A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas

Figure 1

The discovery and validation of a pseudogene methylation signature for non-G-CIMP GBMs. (a) A multistep selection pipeline for identifying a clinically relevant pseudogene methylation signature; (b) risk classification by this signature in a combined discovery cohort of patients treated with RT/TMZ; (c) risk classification in an independent French cohort in term of OS and PFS; (d) risk classification in validation cohorts of patients treated with RT monotherapy; and (e) forest plots of comparison in OS: low-risk vs. high-risk tumors in patients with either RT/TMZ or RT alone.

(a)

(b)

(c)

(d)

(e)